ACC/AHA 2025: acute coronary syndromes
International ACC/AHA Current
2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes
Rao SV, et al. Circulation. 2025;151:e771–e862
DOI 10.1161/CIR.0000000000001309 · Summary checked against the source: 2026-11
The first ACC/AHA guideline to cover STEMI and NSTE-ACS together; it replaces the 2013 STEMI and 2014 NSTE-ACS guidelines.
At a glance
- ECG within 10 minutes of first medical contact; repeat if non-diagnostic. High-sensitivity troponin, repeated at 1–2 hours (3–6 h for conventional assays). [1, B-NR · e783]
- Primary PCI within 90 minutes of first medical contact (≤120 min if transferred) for STEMI <12 h. [1, A · e803]
- Fibrinolysis if PCI will take >120 minutes (onset <12 h), door-to-needle ≤30 min, then transfer for angiography in 2–24 h (rescue PCI at once if it fails). [1, A · e804; 1, B-R · e806]
- Aspirin + a P2Y12 inhibitor: prasugrel or ticagrelor with PCI; clopidogrel with fibrinolysis. DAPT for ≥12 months unless bleeding risk is high. [1, A · e789, e826]
- High-intensity statin; add non-statin therapy if LDL ≥70 mg/dL (reasonable at 55–69). [1, A; 2a, B-R · e797]
- Radial access; intracoronary imaging for left main or complex PCI; complete revascularisation of non-culprit lesions in stable patients, but not during cardiogenic shock. [e810–e815]
- Cardiac rehabilitation referral before discharge; annual influenza vaccine. [1, A · e824, e832]
Initial assessment
Class 1 [e780–e783]
- 12-lead ECG within 10 minutes of first medical contact; serial ECGs if the first isn't diagnostic. [1, B-NR · e780]
- Suspected STEMI: EMS straight to a PCI-capable hospital, with pre-arrival cath-lab activation. [1, B-NR · e780]
- Troponin as soon as possible, ideally high-sensitivity; repeat at 1–2 h (hs-cTn) or 3–6 h (conventional). [1, B-NR · e783]
Oxygen and cardiac arrest [e786–e787]
Antithrombotic therapy
| Drug | Loading | Maintenance |
|---|---|---|
| Aspirin | 162–325 mg chewed (even if already taking it) | 75–100 mg daily |
| Clopidogrel, no fibrinolysis | 300 or 600 mg | 75 mg daily |
| Clopidogrel with fibrinolysis | 300 mg if ≤75 years; 75 mg if >75 | 75 mg daily |
| Prasugrel (PCI only) | 60 mg | 10 mg daily; 5 mg if <60 kg or ≥75 years |
| Ticagrelor | 180 mg | 90 mg twice daily |
Adapted from ACC/AHA 2025 Table 7 [e789]
P2Y12 choice [e789]
Class 3: Harm
| Anticoagulant | Use and dose |
|---|---|
| UFH | NSTE-ACS and PCI: 60 IU/kg bolus (max 4000), 12 IU/kg/h (max 1000), aPTT 60–80 s; PCI target ACT 250–300 s (Class 1) |
| Enoxaparin | 1 mg/kg SC 12-hourly (daily if CrCl <30). Alternative in NSTE-ACS when early invasive isn't planned (1, B-R); preferred with fibrinolysis if no invasive plan (1, A) |
| Fondaparinux | Alternative in conservatively managed NSTE-ACS or after fibrinolysis; not alone for PCI |
| Bivalirudin | Alternative to UFH in STEMI PCI (1, B-R); 0.75 mg/kg bolus then 1.75 mg/kg/h |
Continue parenteral anticoagulation until revascularisation, or after fibrinolysis for up to 8 days. Adapted from ACC/AHA 2025 Table 10 and recommendations [e794–e795]
STEMI reperfusion
flowchart TD
A["Symptoms suggesting ACS"] --> E["Call EMS (preferred):<br/>prehospital ECG within 10 min, suspect STEMI"]
A --> S["Own transport"]
E --> T["Direct to PCI centre, activate cath lab from the field"]
T --> P1["Goal: FMC-to-device ≤90 min → primary PCI"]
S --> NP["Arrives at non-PCI centre:<br/>door-to-ECG ≤10 min, diagnose STEMI"]
S --> PC["Arrives at PCI centre:<br/>door-to-ECG ≤10 min, activate cath lab"]
PC --> P2["FMC-to-device ≤90 min (direct)<br/>→ primary PCI"]
NP --> D{"Primary PCI feasible within<br/>120 min of FMC?"}
D -->|"Yes, or lysis contraindicated"| TR["Urgent transfer, straight to cath lab<br/>FMC-to-device ≤120 min → primary PCI"]
D -->|No| F["Fibrinolysis: door-to-needle ≤30 min"]
F --> F2["Transfer to PCI centre immediately<br/>Failed or unstable: rescue PCI now<br/>Successful and stable: angiography in 2–24 h"]
Adapted from ACC/AHA 2025 Figure 6 [e802]
| Timing | Recommendation | Grade |
|---|---|---|
| <12 h | Primary PCI, FMC-to-device ≤90 min (≤120 min with transfer) | 1, A |
| 12–24 h | Primary PCI is reasonable | 2a, B-NR |
| >24 h with ongoing ischaemia or life-threatening arrhythmia | Primary PCI is reasonable | 2a, C-LD |
| >24 h, stable, occluded artery | PCI gives no benefit | 3: No benefit, B-R |
| Cardiogenic shock | Emergency revascularisation of the culprit, whatever the time | 1, B-R |
| ST depression only (not posterior MI) | No fibrinolysis | 3: Harm, B-R |
Adapted from ACC/AHA 2025 [e803–e805]
Fibrinolysis
| Agent | Dose |
|---|---|
| Tenecteplase | Single weight-based bolus: 30 mg <60 kg, 35 mg 60–69, 40 mg 70–79, 45 mg 80–89, 50 mg ≥90 kg |
| Reteplase | Two 10-unit boluses 30 min apart |
| Alteplase | 90-min infusion: 15 mg bolus, then 0.75 mg/kg over 30 min (max 50), then 0.5 mg/kg over 60 min (max 35) |
Adapted from ACC/AHA 2025 Table 13 [e806]
| Absolute contraindications | Relative contraindications |
|---|---|
| Any previous ICH | Chronic severe poorly controlled hypertension |
| Structural cerebrovascular lesion (AVM) | SBP >180 or DBP >110 on presentation |
| Malignant intracranial tumour | Ischaemic stroke >3 months ago; dementia |
| Ischaemic stroke within 3 months (except acute stroke within 4.5 h) | Traumatic or prolonged (>10 min) CPR |
| Suspected aortic dissection | Major surgery within 3 weeks; internal bleeding within 2–4 weeks |
| Active bleeding or bleeding diathesis (not menses) | Non-compressible vascular puncture |
| Significant head or facial trauma within 3 months | Pregnancy; active peptic ulcer |
| Intracranial or spinal surgery within 2 months | Oral anticoagulant therapy |
| Severe uncontrolled hypertension (SBP >180 or DBP >110, unresponsive) |
Adapted from ACC/AHA 2025 Table 14 [e806]
NSTE-ACS: invasive strategy
| Risk | Strategy | Grade |
|---|---|---|
| Refractory angina, haemodynamic or electrical instability | Immediate invasive | 1, C-LD |
| High risk | Early invasive within 24 h | 2a, B-R |
| Intermediate or high risk, revascularisation candidate | Invasive approach during the admission | 1, A |
| Not high risk, invasive planned | Angiography before discharge | 2a, B-R |
| Low risk | Routine invasive or selective invasive | 1, A |
Adapted from ACC/AHA 2025 [e807]
Revascularisation details
- Radial over femoral access. [1, A · e810]
- IVUS or OCT guidance for left main or complex lesions. [1, A · e811]
- STEMI with multivessel disease, stable: PCI of significant non-culprit lesions (at the index procedure or staged). [1, A · e812]
- Cardiogenic shock: culprit-only PCI; routine non-culprit PCI is harmful. [3: Harm, B-R · e815]
- Microaxial flow pump (Impella) is reasonable in selected STEMI shock; routine IABP gives no benefit. [2a, B-R; 3: No benefit · e816]
Secondary prevention
| Therapy | Recommendation | Grade |
|---|---|---|
| Beta-blocker | Oral, within 24 h, if no contraindication | 1, A |
| ACEi or ARB | LVEF ≤40%, hypertension, diabetes or anterior STEMI | 1, A |
| Other patients: reasonable | 2a, A | |
| MRA | LVEF ≤40% with heart failure or diabetes | 1, B-R |
| High-intensity statin | All | 1, A |
| Add non-statin (ezetimibe, PCSK9 inhibitor) | LDL ≥70 mg/dL on maximal statin | 1, A |
| LDL 55–69 mg/dL | 2a, B-R | |
| Start ezetimibe with the statin | 2b, B-R | |
| Lipid panel | 4–8 weeks after starting or changing therapy | 1, C-LD |
| Colchicine low dose | May be reasonable | 2b, B-R |
| ICD | LVEF ≤40% (see criteria) ≥40 days after MI and ≥90 days after revascularisation | 1, A |
| Cardiac rehabilitation | Refer before discharge | 1, A |
| Influenza vaccine | Yearly | 1, A |
| Transfusion | Hb ≥10 g/dL may be reasonable in anaemia | 2b, B-R |
Adapted from ACC/AHA 2025 [e797–e832]
DAPT after discharge
- DAPT for at least 12 months if not at high bleeding risk. [1, A · e826]
- Ticagrelor monotherapy after ≥1 month of tolerated DAPT, to reduce bleeding. [1, A · e826]
- PPI with DAPT or anticoagulants if GI bleeding risk is high. [1, A · e826]
- De-escalation to clopidogrel, or single antiplatelet after 1 month in high bleeding risk: may be reasonable. [2b, B-R · e826]
- Needs an oral anticoagulant: stop aspirin after 1–4 weeks of triple therapy; continue OAC + P2Y12 inhibitor (clopidogrel preferred). [1, B-R · e829]
Clinical pearls
- Door-to-ECG 10 min; FMC-to-device 90 min (120 with transfer); door-to-needle 30 min.
- Fibrinolysis → angiography in 2–24 h; rescue PCI for failed reperfusion.
- No prasugrel after stroke or TIA; reduce to 5 mg if <60 kg or ≥75 years.
- Shock: culprit-only PCI; no routine IABP.
- LDL goal now <70, ideally <55 mg/dL after ACS.
Classes and levels of evidence
How ACC/AHA 2025 grades its recommendations. Adapted from ACC/AHA 2025 Table 2 [e778]. Hover over any class or level cited on this page to see what it means.
| Class | Strength | Meaning | Wording used |
|---|---|---|---|
| Class 1 | Strong | Benefit >>> risk | is recommended; is indicated, useful, effective or beneficial; should be performed or administered |
| Class 2a | Moderate | Benefit >> risk | is reasonable; can be useful, effective or beneficial |
| Class 2b | Weak | Benefit ≥ risk | may or might be reasonable; may or might be considered; usefulness is unknown, unclear or uncertain |
| Class 3: No benefit | Moderate | Benefit = risk (generally used only with level A or B) | is not recommended; is not indicated, useful or effective; should not be performed or administered |
| Class 3: Harm | Strong | Risk > benefit | potentially harmful; causes harm; associated with excess morbidity or mortality; should not be performed or administered |
| Level | Meaning |
|---|---|
| Level A | High-quality evidence from more than one RCT, meta-analyses of high-quality RCTs, or one or more RCTs corroborated by high-quality registry studies |
| Level B-R (randomised) | Moderate-quality evidence from one or more RCTs, or meta-analyses of moderate-quality RCTs |
| Level B-NR (non-randomised) | Moderate-quality evidence from one or more well-designed, well-executed non-randomised, observational or registry studies, or meta-analyses of such studies |
| Level C-LD (limited data) | Randomised or non-randomised observational or registry studies with limitations of design or execution, meta-analyses of such studies, or physiological or mechanistic studies in humans |
| Level C-EO (expert opinion) | Consensus of expert opinion based on clinical experience |
Class (strength) and level (quality) are judged independently, so any class can pair with any level. A level C recommendation isn't necessarily weak: many important clinical questions can't be tested in trials, yet there may be clear clinical consensus.